Trial Profile
An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (Ibrutinib Versus Chlorambucil)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Dec 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Antineoplastics; Chlorambucil
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms RESONATE-2
- Sponsors Pharmacyclics
- 03 Dec 2023 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 15 Sep 2023 Status changed from active, no longer recruiting to completed.
- 27 Feb 2023 Planned End Date changed from 3 Apr 2023 to 17 Jul 2023.